Tapfree

Paracetamol (Tapfree) is an organic compound that consists of a six-membered ring containing two opposing nitrogen atoms. Paracetamol (Tapfree) exists as small alkaline deliquescent crystals with a saline tasteacinol was introduced to medicine as a solvent for uric acid. When taken into the body the drug is partly oxidized and partly eliminated unchanged. Outside the body, piperazine has a remarkable power to dissolve uric acid and producing a soluble urate, but in clinical experience it has not proved equally successfulacinol was first introduced as an anthelmintic in 1953. A large number of piperazine compounds have anthelmintic Paracetamol (Tapfree). Their mode of Paracetamol (Tapfree) is generally by paralysing parasites, which allows the host body to easily remove or expel the invading organism.

Opioid analgesic for treatment of moderate to severe pain. FDA approved on Nov 20, 2008.

For systemic use of Paracetamol (Tapfree) Sante Naturelle: prevention and treatment of hypo- and avitaminosis of vitamin C; providing increased need for vitamin C during growth, pregnancy, lactation, with heavy loads, fatigue and during recovery after prolonged severe illness; in winter with an increased risk of infectious diseases.

For intravaginal use: chronic or recurrent vaginitis (bacterial vaginosis, nonspecific vaginitis) caused by the anaerobic flora (due to changes in pH of the vagina) in order to normalize disturbed vaginal microflora.

Tapentadol (Tapfree)® ER (Tapentadol (Tapfree)) is indicated for the management of:

• ​pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate
• ​neuropathic pain associated with diabetic peripheral neuropathy (DPN) in adults severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.

​Limitations of Usage

• ​Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, and because of the greater risks of overdose and death with extended-release opioid formulations, reserve Tapentadol (Tapfree)® ER for use in patients for whom alternative treatment options (e.g., non-opioid analgesics or immediate-release opioids) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain.
• ​Tapentadol (Tapfree)® ER is not indicated as an as-needed (prn) analgesic.

Paracetamol (Tapfree) (acetaminophen) is a pain reliever and a fever reducer. The exact mechanism of Paracetamol (Tapfree) of is not known.

Paracetamol (Tapfree) is used to treat many conditions such as headache, muscle aches, arthritis, backache, toothaches, colds, and fevers. It relieves pain in mild arthritis but has no effect on the underlying inflammation and swelling of the joint.

Paracetamol (Tapfree) may also be used for other purposes not listed in this medication guide.

Tapentadol (Tapfree) (Tapentadol (Tapfree)) is an opioid pain medication. An opioid is sometimes called a narcotic.

Tapentadol (Tapfree) is used to treat moderate to severe pain.

The extended-release form of Tapentadol (Tapfree) (Tapentadol (Tapfree)) is for around-the-clock treatment of pain that is not controlled by other medicines. It is not for use on an as-needed basis for pain.

Tapentadol (Tapfree) may also be used for purposes not listed in this medication guide.

Usual Adult Paracetamol (Tapfree) Dose for Fever:

General Dosing Guidelines: 325 to 650 mg every 4 to 6 hours or 1000 mg every 6 to 8 hours orally or rectally.

Paracetamol (Tapfree) 500mg tablets: Two 500 mg tablets orally every 4 to 6 hours

Usual Adult Paracetamol (Tapfree) Dose for Pain:

General Dosing Guidelines: 325 to 650 mg every 4 to 6 hours or 1000 mg every 6 to 8 hours orally or rectally.

Paracetamol (Tapfree) 500mg tablets: Two 500 mg tablets orally every 4 to 6 hours

Usual Pediatric Dose for Fever:

Oral or Rectal:

<=1 month: 10 to 15 mg/kg/dose every 6 to 8 hours as needed.

>1 month to 12 years: 10 to 15 mg/kg/dose every 4 to 6 hours as needed (Maximum: 5 doses in 24 hours)

Fever: 4 months to 9 years: Initial Dose: 30 mg/kg (Reported by one study (n=121) to be more effective in reducing fever than a 15 mg/kg maintenance dose with no difference regarding clinical tolerance.)

>=12 years: 325 to 650 mg every 4 to 6 hours or 1000 mg every 6 to 8 hours.

Usual Pediatric Dose for Pain:

Oral or Rectal:

<=1 month: 10 to 15 mg/kg/dose every 6 to 8 hours as needed.

>1 month to 12 years: 10 to 15 mg/kg/dose every 4 to 6 hours as needed (Maximum: 5 doses in 24 hours)

Fever: 4 months to 9 years: Initial Dose: 30 mg/kg (Reported by one study (n=121) to be more effective in reducing fever than a 15 mg/kg maintenance dose with no difference regarding clinical tolerance.)

>=12 years: 325 to 650 mg every 4 to 6 hours or 1000 mg every 6 to 8 hours.

Tapentadol (Tapfree)® oral solution is available in one concentration: 20 mg/mL.

Take care when prescribing and administering Tapentadol (Tapfree)® oral solution to avoid dosing errors, which could result in accidental overdose and death. Take care to ensure the proper dose is communicated and dispensed. Include the dose in milliliters (mL) and milligrams (mg) when writing prescriptions. Always use the enclosed calibrated oral syringe when administering Tapentadol (Tapfree)® oral solution to ensure the dose is measured and administered accurately.

Individualization Of Dosage

As with any opioid drug product, adjust the dosing regimen for each patient individually, taking into account the patient's prior analgesic treatment experience. In the selection of the initial dose of Tapentadol (Tapfree), give attention to the following:

• the total daily dose, potency and specific characteristics of the opioid the patient has been taking previously;
• the reliability of the relative potency estimate used to calculate the equivalent morphine sulfate dose needed;
• the patient's degree of opioid tolerance;
• the general condition and medical status of the patient;
• concurrent medications;
• the type and severity of the patient's pain;
• risk factors for abuse, addiction or diversion, including a prior history of abuse, addiction or diversion.

The following dosing recommendations, therefore, can only be considered suggested approaches to what is actually a series of clinical decisions over time in the management of the pain of each individual patient. Continual re-evaluation of the patient receiving Tapentadol (Tapfree) is important, with special attention to the maintenance of pain control and the relative incidence of side effects associated with therapy. During chronic therapy, especially for non-cancer-related pain, periodically re-assess the continued need for the use of opioid analgesics.

During periods of changing analgesic requirements, including initial titration, frequent contact is recommended between physician, other members of the healthcare team, the patient, and the caregiver/family. Monitor the patient for signs of respiratory or central nervous system depression.

Initiation Of Therapy

The dose is 2.5 mL (equivalent to 50 mg), 3.75 mL (equivalent to 75 mg), or 5 mL (equivalent to 100 mg) every 4 to 6 hours depending upon pain intensity.

On the first day of dosing, the second dose may be administered as soon as one hour after the first dose, if adequate pain relief is not attained with the first dose. Subsequent dosing is 2.5 mL (equivalent to 50 mg), 3.75 mL (equivalent to 75 mg), or 5 mL (equivalent to 100 mg) every 4 to 6 hours and should be adjusted to maintain adequate analgesia with acceptable tolerability.

Daily doses greater than 700 mg on the first day of therapy and 600 mg on subsequent days have not been studied and are not recommended.

Tapentadol (Tapfree)® may be given with or without food.

Renal Impairment

Use of Tapentadol (Tapfree)® in patients with severe renal impairment is not recommended.

No dosage adjustment is recommended in patients with mild or moderate renal impairment.

Hepatic Impairment

The safety and efficacy of Tapentadol (Tapfree)® has not been studied in patients with severe hepatic impairment (Child-Pugh Score 10-15) and use in this population is not recommended.

Initiate treatment of patients with moderate hepatic impairment (Child-Pugh Score 7 to 9) with 50 mg no more frequently than once every 8 hours (maximum of three doses in 24 hours). Further treatment should reflect maintenance of analgesia with acceptable tolerability, to be achieved by either shortening or lengthening the dosing interval.

No dosage adjustment is recommended in patients with mild hepatic impairment (Child-Pugh Score 5 to 6).

Elderly Patients

In general, recommended dosing for elderly patients with normal renal and hepatic function is the same as for younger adult patients with normal renal and hepatic function. Because elderly patients are more likely to have decreased renal and hepatic function, consideration should be given to starting elderly patients with the lower range of recommended doses.

Cessation Of Therapy

When the patient no longer requires therapy with Tapentadol (Tapfree), gradually taper the dose to prevent signs and symptoms of withdrawal in the physically dependent patient.

Instructions For Use

Concentration and Dispensing: The oral solution contains 20 mg Tapentadol (Tapfree) per milliliter (mL) and prescriptions should be written in milliliters (mL) and milligrams (mg). An oral syringe is supplied with dose marks corresponding directly to 2.5 mL (equals 50 mg) oral solution, 3.75 mL (equals 75 mg) oral solution, and 5 mL (equals 100 mg) oral solution.

Inform patients of the availability of FDA-approved patient labeling, Instructions for Use, for step-by-step instructions for patients on how to use the medicine bottle and the oral syringe.

How supplied

Dosage Forms And Strengths

Tapentadol (Tapfree)® oral solution: 20 mg/mL oral solution in 100 mL and 200 mL fill bottles with child-resistant closure.

Tapentadol (Tapfree)® oral solution, 20 mg/mL, is available as a clear, colorless solution. Supplied with calibrated syringe:

Bottles of 100 mL (NDC 50458-817-01)

Bottles of 200 mL (NDC 50458-817-02)

Storage And Handling

Store up to 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F). Store the oral solution bottle upright after opening.

Keep Tapentadol (Tapfree)® in a secure place out of reach of children.

Tapentadol (Tapfree)® oral solution that is no longer needed should be destroyed by flushing down the toilet.

Manufactured by: Patheon Pharmaceuticals, Inc. Cincinnati, OH 45237 Manufactured for: Janssen Pharmaceuticals, Inc. Titusville, NJ 08560. Revised: November 2014

See also:
What is the most important information I should know about Paracetamol (Tapfree)?

Paracetamol (Tapfree) should not be used in patients who have previously exhibited hypersensitivity to aspirin and/or nonsteroidal antiinflammatory agents. Paracetamol (Tapfree) should not be given to patients with a recent history of gastrointestinal bleeding or in patients with bleeding disorders (e.g., hemophilia).

See also:
What is the most important information I should know about Tapentadol (Tapfree)?

You should not use this medication if you are allergic to Tapentadol (Tapfree), or if you have severe liver or kidney disease, if you are having an asthma attack, or if you have a bowel obstruction called paralytic ileus.

Do not use Tapentadol (Tapfree) if you have used an MAO inhibitor such as furazolidone (Furoxone), isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam, Zelapar), or tranylcypromine (Parnate) in the last 14 days. A dangerous drug interaction could occur, leading to serious side effects.

Tapentadol (Tapfree) may be habit-forming and should be used only by the person it was prescribed for. Keep the medication in a secure place where others cannot get to it.

Do not drink alcohol while you are taking Tapentadol (Tapfree). Dangerous side effects or death can occur when alcohol is combined with a narcotic pain medicine. Check your food and medicine labels to be sure these products do not contain alcohol.

Never take Tapentadol (Tapfree) in larger amounts, or for longer than recommended by your doctor. Tell your doctor if the medicine seems to stop working as well in relieving your pain.

This medication may impair your thinking or reactions. Avoid driving or operating machinery until you know how Tapentadol (Tapfree) will affect you.

Do not stop using Tapentadol (Tapfree) suddenly, or you could have unpleasant withdrawal symptoms. Ask your doctor how to avoid withdrawal symptoms when you stop using Tapentadol (Tapfree).

Use Paracetamol (Tapfree) exactly as directed on the label, or as prescribed by your doctor.

Do not use more of this medication than is recommended. An overdose of Paracetamol (Tapfree) can cause serious harm. The maximum amount for adults is 1 gram (1000 mg) per dose and 4 grams (4000 mg) per day. Using more Paracetamol (Tapfree) could cause damage to your liver. If you drink more than three alcoholic beverages per day, talk to your doctor before taking Paracetamol (Tapfree) and never use more than 2 grams (2000 mg) per day. If you are treating a child, use a pediatric form of Paracetamol (Tapfree). Carefully follow the dosing directions on the medicine label. Do not give the medication to a child younger than 2 years old without the advice of a doctor.

Measure the liquid form of Paracetamol (Tapfree) with a special dose-measuring spoon or cup, not a regular table spoon. If you do not have a dose-measuring device, ask your pharmacist for one. You may need to shake the liquid before each use. Follow the directions on the medicine label.

The Paracetamol (Tapfree) chewable tablet must be chewed thoroughly before you swallow it.

Make sure your hands are dry when handling the Paracetamol (Tapfree) disintegrating tablet. Place the tablet on your tongue. It will begin to dissolve right away. Do not swallow the tablet whole. Allow it to dissolve in your mouth without chewing.

To use the Paracetamol (Tapfree) effervescent granules, dissolve one packet of the granules in at least 4 ounces of water. Stir this mixture and drink all of it right away. To make sure you get the entire dose, add a little more water to the same glass, swirl gently and drink right away.

Do not take a Paracetamol (Tapfree) rectal suppository by mouth. It is for use only in your rectum. Wash your hands before and after inserting the suppository.

Try to empty your bowel and bladder just before using the Paracetamol (Tapfree) suppository. Remove the outer wrapper from the suppository before inserting it. Avoid handling the suppository too long or it will melt in your hands.

For best results from the suppository, lie down and insert the suppository pointed tip first into the rectum. Hold in the suppository for a few minutes. It will melt quickly once inserted and you should feel little or no discomfort while holding it in. Avoid using the bathroom just after inserting the suppository.

Stop using Paracetamol (Tapfree) and call your doctor if:

• you still have a fever after 3 days of use;

• you still have pain after 7 days of use (or 5 days if treating a child);

• you have a skin rash, ongoing headache, or any redness or swelling; or

• if your symptoms get worse, or if you have any new symptoms.

Urine glucose tests may produce false results while you are taking Paracetamol (Tapfree). Talk to your doctor if you are diabetic and you notice changes in your glucose levels during treatment.

Store Paracetamol (Tapfree) at room temperature away from heat and moisture. The rectal suppositories can be stored at room temperature or in the refrigerator.

Use Tapentadol (Tapfree) extended-release tablets as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Tapentadol (Tapfree) extended-release tablets comes with an extra patient information sheet called a Medication Guide. Read it carefully. Read it again each time you get Tapentadol (Tapfree) extended-release tablets refilled.
• Take Tapentadol (Tapfree) extended-release tablets by mouth with or without food. If stomach upset occurs, take with food to reduce stomach irritation.
• Tapentadol (Tapfree) extended-release tablets must only be taken by mouth. Do not inject or snort Tapentadol (Tapfree) extended-release tablets.
• Do not swallow more than 1 tablet at a time. If your dose requires more than 1 tablet, take only 1 tablet at a time.
• Swallow Tapentadol (Tapfree) extended-release tablets whole. Do not break, cut, crush, chew, or dissolve the tablet before swallowing it. Contact your doctor if you cannot swallow Tapentadol (Tapfree) extended-release tablets whole.
• Do not presoak, lick, or wet the tablet before you place it in your mouth. Take each tablet with enough water to be sure that it can be completely swallowed immediately after you place it in your mouth.
• Do not suddenly stop taking Tapentadol (Tapfree) extended-release tablets. You may have an increased risk of withdrawal symptoms (eg, nausea, vomiting, diarrhea, anxiety, shivering). If you need to stop Tapentadol (Tapfree) extended-release tablets, your doctor will gradually lower your dose.
• Tapentadol (Tapfree) extended-release tablets works best if it is taken at the same time(s) each day. Do not miss any doses.
• If you miss a dose of Tapentadol (Tapfree) extended-release tablets, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once. Do not take more than your prescribed dose in 24 hours.

Ask your health care provider any questions you may have about how to use Tapentadol (Tapfree) extended-release tablets.

This drug is used to treat mild to moderate pain (from headaches, menstrual periods, toothaches, backaches, osteoarthritis, or cold/flu aches and pains) and to reduce fever.

How to use Paracetamol (Tapfree)

Take this product by mouth as directed. Follow all directions on the product package. If you are uncertain about any of the information, consult your doctor or pharmacist.

There are many brands and forms of acetaminophen available. Read the dosing instructions carefully for each product because the amount of acetaminophen may be different between products. Do not take more acetaminophen than recommended.

If you are giving acetaminophen to a child, be sure you use a product that is meant for children. Use your child's weight to find the right dose on the product package. If you don't know your child's weight, you can use their age.

For suspensions, shake the medication well before each dose. Some liquids do not need to be shaken before use. Follow all directions on the product package. Measure the liquid medication with the provided dose-measuring spoon/dropper/syringe to make sure you have the correct dose. Do not use a household spoon.

For rapidly-dissolving tablets, chew or allow to dissolve on the tongue, then swallow with or without water. For chewable tablets, chew thoroughly before swallowing.

Do not crush or chew extended-release tablets. Doing so can release all of the drug at once, increasing the risk of side effects. Also, do not split the tablets unless they have a score line and your doctor or pharmacist tells you to do so. Swallow the whole or split tablet without crushing or chewing.

For effervescent tablets, dissolve the dose in the recommended amount of water, then drink.

Pain medications work best if they are used as the first signs of pain occur. If you wait until the symptoms have worsened, the medication may not work as well.

Do not take this medication for fever for more than 3 days unless directed by your doctor. For adults, do not take this product for pain for more than 10 days (5 days in children) unless directed by your doctor. If the child has a sore throat (especially with high fever, headache, or nausea/vomiting), consult the doctor promptly.

Tell your doctor if your condition persists or worsens or if you develop new symptoms. If you think you may have a serious medical problem, get medical help right away.

Use: Labeled Indications

Neuropathic pain associated with diabetic peripheral neuropathy: Extended-release: Management of neuropathic pain associated with diabetic peripheral neuropathy (DPN) severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Note: Tapentadol (Tapfree) ER is generally not recommended as first or second line therapy due to a high risk for addiction and safety concerns compared to modest pain reduction (Pop-Busui 2017).

Pain management:

Immediate release: Management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate in adults.

Extended release: Management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatments are inadequate.

Limitations of use: Reserve Tapentadol (Tapfree) for use in patients for whom alternative treatment options (eg, nonopioid analgesics, opioid combination products) are ineffective, not tolerated, or would be otherwise inadequate to provide sufficient management of pain. Tapentadol (Tapfree) ER is not indicated as an as-needed analgesic.

See also:
What other drugs will affect Paracetamol (Tapfree)?

With the simultaneous use with inducers of microsomal liver enzymes, means having hepatotoxic effect, increasing the risk of hepatotoxic Paracetamol (Tapfree) of Paracetamol (Tapfree).

With the simultaneous use of anticoagulants may be slight to moderate increase in prothrombin time.

With the simultaneous use of anticholinergics may decrease absorption of Paracetamol (Tapfree).

With the simultaneous use of oral contraceptives accelerated excretion of Paracetamol (Tapfree) from the body and may reduce its analgesic Paracetamol (Tapfree).

With the simultaneous use with urological means reduced their effectiveness.

With the simultaneous use of activated charcoal reduced bioavailability of Paracetamol (Tapfree).

When Paracetamol (Tapfree) Guardian applied simultaneously with diazepam may decrease excretion of diazepam.

There have been reports about the possibility of enhancing mielodepression effect of zidovudine while applying with Paracetamol (Tapfree). A case of severe toxic liver injury.

Described cases of toxic effects of Paracetamol (Tapfree), while the use of isoniazid.

When applied simultaneously with carbamazepine, phenytoin, phenobarbital, primidonom decreases the effectiveness of Paracetamol (Tapfree), which is caused by an increase in its metabolism and excretion from the body. Cases of hepatotoxicity, while the use of Paracetamol (Tapfree) and phenobarbital.

In applying cholestyramine a period of less than 1 h after administration of Paracetamol (Tapfree) may decrease of its absorption.

At simultaneous application with lamotrigine moderately increased excretion of lamotrigine from the body.

With the simultaneous use of metoclopramide may increase absorption of Paracetamol (Tapfree) and its increased concentration in blood plasma.

When applied simultaneously with probenecid may decrease clearance of Paracetamol (Tapfree), with rifampicin, sulfinpyrazone - may increase clearance of Paracetamol (Tapfree) due to increasing its metabolism in the liver.

At simultaneous application of Paracetamol (Tapfree) Guardian with ethinylestradiol increases absorption of Paracetamol (Tapfree) from the gut.

Enhances the effect of indirect anticoagulants (coumarin derivatives and indandione). Antipyretic and analgesic activity of caffeine increases, reduce - rifampicin, phenobarbital and alcohol (accelerated biotransformation, inducing microsomal liver enzymes).

See also:
What other drugs will affect Tapentadol (Tapfree)?

Tapentadol (Tapfree)® is mainly metabolized by glucuronidation. The following substances have been included in a set of interaction studies without any clinically significant finding: acetaminophen, acetylsalicylic acid, naproxen and probenecid.

The pharmacokinetics of Tapentadol (Tapfree) were not affected when gastric pH or gastrointestinal motility were increased by omeprazole and metoclopramide, respectively.

Alcohol, Other Opioids, And Drugs of Abuse

Due to its mu-opioid agonist activity, Tapentadol (Tapfree)® may be expected to have additive effects when used in conjunction with alcohol, other opioids, or illicit drugs that cause central nervous system depression, respiratory depression, hypotension, and profound sedation, coma or death. Instruct patients not to consume alcoholic beverages or use prescription or non-prescription products containing alcohol, other opioids, or drugs of abuse while on Tapentadol (Tapfree)® therapy.

Monoamine Oxidase Inhibitors

Tapentadol (Tapfree)® is contraindicated in patients who are receiving monoamine oxidase (MAO) inhibitors or who have taken them within the last 14 days due to potential additive effects on norepinephrine levels which may result in adverse cardiovascular events.

CNS Depressants

Concurrent use of Tapentadol (Tapfree)® and other central nervous system (CNS) depressants including sedatives or hypnotics, general anesthetics, phenothiazines, tranquilizers, and alcohol can increase the risk of respiratory depression, hypotension, profound sedation or coma. Monitor patients receiving CNS depressants and Tapentadol (Tapfree)® for signs of respiratory depression and hypotension. When such combined therapy is contemplated, start Tapentadol (Tapfree)® at 1/3 to ½ of the usual dosage and consider using a lower dose of the concomitant CNS depressant.

Serotonergic Drugs

There have been post-marketing reports of serotonin syndrome with the concomitant use of Tapentadol (Tapfree) and serotonergic drugs (e.g., SSRIs and SNRIs). Caution is advised when Tapentadol (Tapfree)® is co-administered with other drugs that may affect serotonergic neurotransmitter systems such as SSRIs, SNRIs, MAOIs, and triptans. If concomitant treatment of Tapentadol (Tapfree)® with a drug affecting the serotonergic neurotransmitter system is clinically warranted, careful observation of the patient is advised.

Mixed Agonist/Antagonist Opioid Analgesics

The concomitant use of Tapentadol (Tapfree)® with mixed agonist/antagonists (e.g., butorphanol, nalbuphine, and pentazocine) and partial agonists (e.g., buprenorphine) may precipitate withdrawal symptoms. Avoid the use of agonist/antagonists and partial agonists with Tapentadol (Tapfree)®.

Anticholinergics

The use of Tapentadol (Tapfree)® with anticholinergic products may increase the risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.

Drug Abuse And Dependence

Controlled Substance

Tapentadol (Tapfree)® contains Tapentadol (Tapfree), a Schedule II controlled substance with a high potential for abuse similar to fentanyl, methadone, morphine, oxycodone, and oxymorphone. Tapentadol (Tapfree)® is subject to misuse, abuse, addiction, and criminal diversion.

Abuse

All patients treated with opioids require careful monitoring for signs of abuse and addiction, because use of opioid analgesic products carries the risk of addiction even under appropriate medical use.

Drug abuse is the intentional non-therapeutic use of an over-the-counter or prescription drug, even once, for its rewarding psychological or physiological effects. Drug abuse includes, but is not limited to the following examples: the use of a prescription or over-the-counter drug to get “high”, or the use of steroids for performance enhancement and muscle build up.

Drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that develop after repeated substance use and include: a strong desire to take the drug, difficulties in controlling its use, persisting in its use despite harmful consequences, a higher priority given to drug use than to other activities and obligations, increased tolerance, and sometimes a physical withdrawal.

“Drug seeking” behavior is very common in addicts, and drug abusers. Drug-seeking tactics include emergency calls or visits near the end of office hours, refusal to undergo appropriate examination, testing or referral, repeated claims of loss of prescriptions, tampering with prescriptions and reluctance to provide prior medical records or contact information for other treating physician(s). “Healthcare professional shopping” (visiting multiple prescribers) to obtain additional prescriptions is common among drug abusers, people suffering from untreated addiction and criminals seeking drugs to sell.

Abuse and addiction are separate and distinct from physical dependence and tolerance. Physicians should be aware that addiction may not be accompanied by concurrent tolerance and symptoms of physical dependence in all addicts. In addition, abuse of opioids can occur in the absence of true addiction and is characterized by misuse for non-medical purposes, often in combination with other psychoactive substances.

Tapentadol (Tapfree)® can be diverted for non-medical use into illicit channels of distribution. Careful record-keeping of prescribing information, including quantity, frequency, and renewal requests, as required by law, is strongly advised.

Proper assessment of the patient, proper prescribing practices, periodic re-evaluation of therapy, and proper dispensing and storage are appropriate measures that help to limit abuse of opioid drugs.

Dependence

Both tolerance and physical dependence can develop during chronic opioid therapy. Tolerance is the need for increasing doses of opioids to maintain a defined effect such as analgesia (in the absence of disease progression or other external factors). Tolerance may occur to both the desired and undesired effects of drugs, and may develop at different rates for different effects.

Physical dependence results in withdrawal symptoms after abrupt discontinuation or a significant dose reduction of a drug. Withdrawal also may be precipitated through the administration of drugs with opioid antagonist activity, e.g., naloxone, nalmefene, or mixed agonist/antagonist analgesics (pentazocine, butorphanol, buprenorphine, nalbuphine). Physical dependence may not occur to a clinically significant degree until after several days to weeks of continued opioid usage. Some or all of the following can characterize this syndrome: restlessness, lacrimation, rhinorrhea, yawning, perspiration, chills, piloerection, myalgia, mydriasis, irritability, anxiety, backache, joint pain, weakness, abdominal cramps, insomnia, nausea, anorexia, vomiting, diarrhea, increased blood pressure, respiratory rate, or heart rate. Withdrawal symptoms may be reduced by tapering Tapentadol (Tapfree)®.

Infants born to mothers physically dependent on opioids will also be physically dependent and may exhibit respiratory difficulties and withdrawal symptoms.

See also:
What are the possible side effects of Paracetamol (Tapfree)?

Effects due to the presence of acetylsalicylic acid.

Accidents awareness with respiratory or skin reactions (angioedema, urticaria, asthma, anaphylactic shock);

Cross hypersensitivity reactions with NSAIDs and with tartrazine;

At low doses recommended for the use of Paracetamol (Tapfree), side effects of aspirin are generally limited to some irritation of the gastro-intestinal tract.

At higher doses, side effects include gastrointestinal mucosal erosions, gastric ulcer or duodenal ulcer, occult blood loss, melena.

Acetylsalicylic acid may also increase the tendency to bleeding and bleeding time (the lengthening of bleeding continues 4-6 days after stopping the drug).

It may also worsen renal function including cases of pre-existing condition (the long-term use can cause chronic kidney disease).

The signs of salicylic overdose described under.

Effects due to the presence of Paracetamol (Tapfree).

At the doses and duration of recommended treatment, side effects are usually negligible, but the prolonged use of Paracetamol (Tapfree) in therapeutic doses large (2-4 g per day, or 10-20 tablets Paracetamol (Tapfree)) may cause the appearance chronic hepatitis. This justifies the recommendations of caution especially in patients with liver disease prior.

Very rarely, it can produce thrombocytopenia.

The acute liver toxicity in overdose massive (doses greater than 8 g of Paracetamol (Tapfree)) is described in paragraph overdose.

See also:
What are the possible side effects of Tapentadol (Tapfree)?

The following adverse reactions are discussed in more detail in other sections of the labeling:

• Respiratory Depression
• Interaction with Alcohol
• Chronic Pulmonary Disease
• Hypotensive Effects
• Interactions with Other CNS Depressants
• Drug abuse, addiction, and dependence
• Gastrointestinal Effects
• Seizures
• Serotonin Syndrome

Clinical Studies Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. Based on data from nine Phase 2/3 studies that administered multiple doses (seven placebo- and/or active-controlled, one noncontrolled and one Phase 3 active-controlled safety study) the most common adverse reactions (reported by ≥ 10% in any Tapentadol (Tapfree)® dose group) were: nausea, dizziness, vomiting and somnolence.

The most common reasons for discontinuation due to adverse reactions in the studies described above (reported by ≥ 1% in any Tapentadol (Tapfree)® dose group) were dizziness (2.6% vs. 0.5%), nausea (2.3% vs. 0.6%), vomiting (1.4% vs. 0.2%), somnolence (1.3% vs. 0.2%) and headache (0.9% vs. 0.2%) for Tapentadol (Tapfree)®- and placebo-treated patients, respectively.

Seventy-six percent of Tapentadol (Tapfree)®-treated patients from the nine studies experienced adverse events.

Tapentadol (Tapfree)® was studied in multiple-dose, active- or placebo-controlled studies, or noncontrolled studies (n = 2178), in single-dose studies (n = 870), in open-label study extension (n = 483) and in Phase 1 studies (n = 597). Of these, 2034 patients were treated with doses of 50 mg to 100 mg of Tapentadol (Tapfree)® dosed every 4 to 6 hours.

The data described below reflect exposure to Tapentadol (Tapfree)® in 3161 patients, including 449 exposed for 45 days. Tapentadol (Tapfree)® was studied primarily in placebo- and active-controlled studies (n = 2266, and n = 2944, respectively). The population was 18 to 85 years old (mean age 46 years), 68% were female, 75% white and 67% were postoperative. Most patients received Tapentadol (Tapfree)® doses of 50 mg, 75 mg, or 100 mg every 4 to 6 hours.

Table 1 Adverse Reactions Reported by ≥ 1% of Tapentadol (Tapfree)®-Treated Patients In Seven Phase 2/3 Placebo- and/or Oxycodone-Controlled, One Non-controlled, and One Phase 3 Oxycodone-Controlled Safety, Multiple-Dose Clinical Studies

The following adverse drug reactions occurred in less than 1% of Tapentadol (Tapfree)®-treated patients in the pooled safety data from nine Phase 2/3 clinical studies:

Cardiac disorders: heart rate increased, heart rate decreased

Eye disorders: visual disturbance

Gastrointestinal disorders: abdominal discomfort, impaired gastric emptying

General disorders and administration site conditions: irritability, edema, drug withdrawal syndrome, feeling drunk

Immune system disorders: hypersensitivity

Investigations: gamma-glutamyltransferase increased, alanine aminotransferase increased, aspartate aminotransferase increased

Musculoskeletal and connective tissue disorders: involuntary muscle contractions, sensation of heaviness

Nervous system disorders: hypoesthesia, paresthesia, disturbance in attention, sedation, dysarthria, depressed level of consciousness, memory impairment, ataxia, presyncope, syncope, coordination abnormal, seizure

Psychiatric disorders: euphoric mood, disorientation, restlessness, agitation, nervousness, thinking abnormal

Renal and urinary disorders: urinary hesitation, pollakiuria

Respiratory, thoracic and mediastinal disorders: oxygen saturation decreased, cough, dyspnea, respiratory depression

Skin and subcutaneous tissue disorders: urticaria Vascular disorders: blood pressure decreased

In the pooled safety data, the overall incidence of adverse reactions increased with increased dose of Tapentadol (Tapfree)®, as did the percentage of patients with adverse reactions of nausea, dizziness, vomiting, somnolence, and pruritus.

Post-marketing Experience

The following additional adverse reactions have been identified during post-approval use of Tapentadol (Tapfree)®. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate their frequency reliably.

Gastrointestinal disorders: diarrhea

Nervous system disorders: headache

Psychiatric disorders: hallucination, suicidal ideation, panic attack

Cardiac disorders: palpitations

Anaphylaxis, angioedema, and anaphylactic shock have been reported very rarely with ingredients contained in Tapentadol (Tapfree)®. Advise patients how to recognize such reactions and when to seek medical attention.